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Abstract The diagnosis of medulloblastoma likely
encompasses several distinct entities, with recent evidence
forthe existenceof at least four unique molecular subgroups
that exhibit distinct genetic, transcriptional, demographic,
and clinical features. Assignment of molecular subgroup
throughroutineproﬁlingofhigh-qualityRNAonexpression
microarrays is likely impractical in the clinical setting. The
planning and execution of medulloblastoma clinical trials
that stratify by subgroup, or which are targeted to a speciﬁc
subgroup requires technologies that can be economically,
rapidly, reliably, and reproducibly applied to formalin-ﬁxed
parafﬁn embedded (FFPE) specimens. In the current study,
we have developed an assay that accurately measures the
expression level of 22 medulloblastoma subgroup-speciﬁc
signature genes (CodeSet) using nanoString nCounter
Technology. Comparison of the nanoString assay with
Affymetrix expression array data on a training series of 101
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DOI 10.1007/s00401-011-0899-7medulloblastomas of known subgroup demonstrated a high
concordance (Pearson correlation r = 0.86). The assay was
validated on a second set of 130 non-overlapping medullo-
blastomas of known subgroup, correctly assigning 98%
(127/130) of tumors to the appropriate subgroup. Repro-
ducibility was demonstrated by repeating the assay in three
independent laboratories in Canada, the United States, and
Switzerland. Finally, the nanoStringassaycould conﬁdently
predict subgroup in 88% of recent FFPE cases, of which
100% had accurate subgroup assignment. We present an
assay based on nanoString technology that is capable of
rapidly, reliably, and reproducibly assigning clinical FFPE
medulloblastoma samples to their molecular subgroup, and
which is highly suited for future medulloblastoma clinical
trials.
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Introduction
Currently, patients enrolled on clinical trials for medullo-
blastoma are stratiﬁed on the basis of clinical variables
such as age, extent of resection, presence of metastases,
and histology. Recently, several publications have reported
that the histological entity known as medulloblastoma
comprises several distinct molecular variants or subgroups
[1, 6, 12, 17]. Despite variation in the number and
nomenclature of the subgroups identiﬁed, the current
consensus is that medulloblastoma comprises four core
subgroups (i.e., WNT, SHH, Group C, and Group D), with
mounting evidence for clinically relevant substructure
(subtypes within the subgroups) [1, 11]. Each subgroup
exhibits distinct demographics, transcriptomics, genomics,
and clinical outcomes [1, 12]. While some subgroups are
well treated, or debatably even over-treated using current
protocols (i.e., WNT medulloblastomas), others have a
very poor outcome (i.e., Group C medulloblastomas).
Additionally, as the subgroups have very different molec-
ular genetic proﬁles, any successful strategies for targeted
therapy will likely be subgroup speciﬁc (i.e., SMO inhib-
itors for SHH subgroup tumors). Although the retrospective
classiﬁcation of various medulloblastoma cohorts into
molecular subgroups has been scientiﬁcally insightful,
medulloblastoma sub-grouping has not yet been applied in
the setting of a prospective clinical trial for either patient
stratiﬁcation or patient selection for targeted therapy.
There is currently no well-accepted gold standard test
for medulloblastoma subgroup assignment. The method-
ology used in most of the published literature on
medulloblastoma subgroups has been the analysis of high-
quality RNA from ﬂash-frozen samples that were analyzed
using genome-wide transcriptional microarrays. Although
an excellent tool for retrospective research studies, gene
expression microarray proﬁling is likely inappropriate and
inadequate for routine clinical use or for clinical trials due
to the need for large amounts of high-quality RNA (from
frozen tumor tissue), lot-to-lot variability of microarrays,
bioinformatic complexity, and relatively high cost. Spe-
ciﬁcally, RNA isolated from formalin-ﬁxed parafﬁn
embedded (FFPE) medulloblastoma samples is frag-
mented, and not suitable for hybridization to expression
microarrays. In both routine clinical settings and clinical
trials, a rapid test completion time is critical, making
microarray platforms an inefﬁcient diagnostic tool.
In contrast, medulloblastoma subgroup assignment
using immunohistochemistry (IHC) performed on FFPE
cases has shown recent promise. We recently reported a
four-antibody protocol for classiﬁcation of medulloblasto-
mas, and applied this method to a large series (n = 294) of
FFPE medulloblastomas on tissue microarrays (TMAs),
effectively classifying *98% of samples [12]. Ellison
et al. [3] recently reported an IHC-based assay for classi-
fying medulloblastomas into WNT, SHH, and non-WNT/
SHH subgroups using a distinct set of antibodies. Chal-
lenges in bringing IHC to the clinic for subgroup
assignment remain due to lot-to-lot variability of antibod-
ies, inter-institutional differences in tissue ﬁxation and
embedding, technical variations of IHC, and inter and
intra-observer variability in image interpretation. The
inclusion of IHC markers for subgroup ascertainment in
future clinical trials would likely be complimented by
another orthogonal technology, to conﬁrm subgroup afﬁl-
iation as identiﬁed by IHC, and provide treating clinicians
with conﬁdence that the correct subgroup has been
assigned. By its very nature, IHC is likely limited to one or
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123two markers per subgroup, and these markers must be
proteins excluding the use of non-coding RNAs as markers.
While some of the described antibodies will likely become
widely used as clinical tests, complimentary and conﬁr-
matory technologies may be required in the setting of a
clinical trial.
To develop and optimize a more rapid, reliable, repro-
ducible, and economical method for medulloblastoma
classiﬁcation, we have taken advantage of the recently
described nanoString nCounter System, a non-enzymatic
multiplexed assay that uses sequence-speciﬁc probes to
digitally measure target abundance (i.e., mRNA) within a
given sample [5, 7, 9]. Based on nanoString technology,
and using information from existing gene expression array
data [12], we designed a custom CodeSet (i.e., probe
library) consisting of interrogating probes against 22
medulloblastoma subgroup-speciﬁc signature genes. We
tested our nanoString assay on our own medulloblastoma
series of known subgroup afﬁliation prior to validation of
the assay on three non-overlapping medulloblastoma
cohorts with known subgroup afﬁliation. Finally, the assay
was applied to a large series of FFPE medulloblastomas to
establish its applicability in the classiﬁcation of routine
clinical samples as would be encountered in the setting of a
prospective clinical trial.
Patients and methods
Patient samples
All samples were obtained in accordance with the Research
Ethics Board at the Hospital for Sick Children (Toronto,
Canada). Primary medulloblastomas comprising the train-
ing series for nanoString (n = 101) have been previously
described [10, 12, 13]. Samples contributing to the vali-
dation series (n = 130) have been previously described and
were obtained as total RNA extracted from fresh-frozen
tissue from the DKFZ (Heidelberg, Germany; Remke ser-
ies, n = 55), the Dana-Farber Cancer Institute (Boston,
USA; Cho series, n = 39) [1], and the Academic Medical
Center (Amsterdam, the Netherlands; Kool series, n = 36)
[6]. Formalin-ﬁxed parafﬁn embedded (FFPE) cases
(n = 84) were obtained as parafﬁn sections from the
Hospital for Sick Children (Toronto, Canada; n = 34),
Johns Hopkins University (Baltimore, USA; n = 25), and
the DKFZ (Heidelberg, Germany; n = 25).
NanoString CodeSet design and expression
quantiﬁcation
Signature genes for each medulloblastoma subgroup were
included in the CodeSet on the basis of their observed
subgroup-speciﬁc expression, as previously determined by
Affymetrix exon array analysis [10, 12]. Speciﬁcally,
conventional t test statistics restricted on the proportion of
false discoveries (FDR) were employed to compare each
subgroup to the remaining three subgroups in order to
identify the most highly signiﬁcant, differentially expres-
sed genes. The CodeSet was designed to consist of a total
of 25 genes with 5–6 signature genes included for each
subgroup: WNT (WIF1, TNC, GAD1, DKK2, EMX2), SHH
(PDLIM3, EYA1, HHIP, ATOH1, SFRP1), Group C
(IMPG2, GABRA5, EGFL11, NRL, MAB21L2, NPR3),
Group D (KCNA1, EOMES, KHDRBS2, RBM24, UNC5D,
OAS1). Three housekeeping genes (ACTB, GAPDH, and
LDHA) were also included in the CodeSet for biological
normalization purposes. Probe sets for each gene in the
CodeSet were designed and synthesized at nanoString
Technologies.
Total RNA (100 ng) from fresh-frozen tissue and FFPE
material was analyzed using the nanoString nCounter
Analysis System at the University Health Network
Microarray Centre (Toronto, Canada), the Oncogenomics
Core Facility at the University of Miami (Miami, USA),
and the Frontiers in Genetics Facility at the University of
Geneva (Geneva, Switzerland). All procedures related to
mRNA quantiﬁcation including sample preparation,
hybridization, detection, and scanning were carried out as
recommended by nanoString Technologies.
Sample processing
Total RNA was extracted from fresh-frozen tissue using the
Trizol method (Invitrogen) according to the manufacturer’s
instructions. For FFPE samples, *3–5 parafﬁn sections per
sample were ﬁrst deparafﬁnized with xylene prior to RNA
extraction using the RNeasy FFPE kit (Qiagen) as directed
by the manufacturer. RNA concentration was measured
using a Nanodrop 1000 instrument (Nanodrop) and RNA
integrity was assessed using an Agilent 2100 bioanalyzer at
The Centre for Applied Genomics at the Hospital for Sick
Children (Toronto, Canada).
NanoString data processing and class prediction
analysis
Raw nanoString counts for each gene within each experi-
ment were subjected to a technical normalization using the
counts obtained for positive control probe sets prior to a
biological normalization using the three housekeeping
genes included in the CodeSet. Normalized data was log2-
transformed and then used as input for class prediction
analysis.
A series of medulloblastomas with known subgroup
afﬁliation (n = 101) were used to establish a training
Acta Neuropathol (2012) 123:615–626 617
123dataset for subsequent class prediction analysis of inde-
pendent cohorts utilized in the study. Various class
prediction algorithms were assessed by a tenfold cross-
validation scheme, using a set of scoring indices to estab-
lish a pipeline for prediction of medulloblastoma
subgroups using nanoString data derived from the training
series. Based on superior performance in cross-validation
analysis, the PAM method [18] was selected for all
downstream class prediction analyses.
All class prediction analyses were performed in the R
statistical programming environment (v2.13). Implemen-
tations of the class prediction algorithms were imported
from the following R packages: MASS v7.3 (linear dis-
criminant analysis; LDA), class v7.3 (k-nearest neighbor;
KNN), e1071 v1.5 (support vector machine; SVM), nnet
v7.3 (multinomial log-linear model; MULT), and pamr
v1.51 (prediction analysis for microarrays; PAM) [18].
During cross-validation, the training set of 101 samples
was randomly split into 10 partitions. Each class predictor
was trained on nine of the partitions, and the performance
of the predictor was subsequently tested on the one
remaining partition. Each of the 10 partitions was used as
the testing set in turn for a round of cross-validation, for a
total of 10,000 rounds of cross-validation, which was
repeated three times with reproducible results.
The scoring indices used during testing were accuracy,
Jaccard similarity index, Rand index, adjusted Rand index,
and Fowlkes–Mallows index. The latter four indices are
different indices for determining the similarity between
two groupings, which are the known and predicted classi-
ﬁcations of samples in the current analysis. These indices
serve as more stringent measures of accuracy in multi-class
prediction. Aside from the accuracy measures (validity),
the reliabilities of the predictors were also determined
using Shannon entropy as a measure of uncertainty. Pre-
dictors with varying predicted classes for the same sample
across the cross-validation rounds have higher entropy
values, and are hence less reliable.
Since the model parameters for SVM can affect the
prediction performance, these parameters were optimized
by a grid search in a separate round of cross-validation.
The ranges of searched parameter values were: [2
-5,2
15]
for C; [2
-15,2
3] for gamma; [2, 8] for degree; [-1, 1] for
coef0. Further, SVM using different kernels (linear, radial
basis, polynomial, and sigmoid) were assessed, and the
kernel with the best performance was selected. Similarly
for KNN, the best model was selected from models with
different k.
Regression analysis of prediction accuracy
Cumulative prediction accuracy was modeled as a function
of FFPE sample age. The prediction accuracies were ﬁrst
calculated for each sample age year-group. The cumulative
accuracies were then determined by calculating the
cumulative sum of the accuracies, weighted by the size of
each year-group. The data were ﬁtted using a 5-parameter
logistic regression model, as implemented in the drc v2.1 R
package. The maximum asymptote parameter (D) was
constrained at 1 in order to reﬂect the high accuracy the
predictor achieved with recent FFPE samples.
RNA integrity assessment
RNA derived from FFPE material was subjected to Agilent
Bioanalyzer analysis to determine RNA integrity. Smear
analysis was performed using the Agilent 2100 expert
software to determine the proportion of RNA C300
nucleotides (nt) within a given sample.
Results
Establishment of a nanoString assay
for medulloblastoma subgroup identiﬁcation
To identify a set of genes that would facilitate the pro-
spective classiﬁcation of medulloblastomas into the four
core subgroups of the disease, we re-analyzed gene
expression array data from a large series of primary cases
of known subgroup [10, 12]. Supervised analysis identiﬁed
signature genes that demonstrate subgroup-speciﬁc
expression patterns across the four molecular subgroups
(Table 1). From this data, we selected 5–6 highly signiﬁ-
cant signature genes per subgroup for inclusion in a custom
nanoString CodeSet (probe library) for downstream clas-
siﬁcation analysis (Supplementary Figure 1). As an initial
evaluation of our nanoString CodeSet’s capacity to mea-
sure the gene expression level of medulloblastoma
signature genes, we ﬁrst proﬁled a series of 101 primary
cases (training series) for which we also had matching
Affymetrix exon array data [10, 12]. Comparison of the
newly generated nanoString data with the published exon
array data for this training series showed remarkable sim-
ilarity between the two datasets (Fig. 1a; Supplementary
Figure 2). Pearson correlation analysis conﬁrmed a high
degree of concordance (r = 0.86) between the two plat-
forms (Fig. 1b; Supplementary Figure 3). Using a series of
well-described class prediction algorithms, we evaluated
the capacity of our custom CodeSet to accurately classify
samples within the training series into the correct subgroup.
Following 10,000 iterations in cross-validation analysis,
the PAM algorithm [18] exhibited the most accurate class
prediction results, reliably assigning 98/101 (*97%) cases
in the training series (Fig. 1c, d; Supplementary Figure 4).
In this cross-validation exercise, PAM outperformed other
618 Acta Neuropathol (2012) 123:615–626
123commonly used class prediction methods such as Support
Vector Machine (SVM) and K-Nearest Neighbor (KNN).
Isolation of tumor RNA, performance of the nanoString
assay, and bioinformatic analysis required 3–4 days for
completion, at a cost of approximately $60 USD per
sample. These data suggest that we have generated an
assay capable of predicting medulloblastoma subgroup
afﬁliation with high accuracy that is additionally both rapid
and economical.
Validation of the nanoString classiﬁer on multiple
published medulloblastoma cohorts
To validate our nanoString CodeSet approach to medullo-
blastomasubgroupprediction,weobtainedthreeindependent
validation cohorts (n = 130) with well-documented molec-
ular proﬁles including subgroup afﬁliation as determined in
recently published gene expression array studies [1, 6].
NanoString proﬁling of the 130 cases comprising this vali-
dationseriesfollowedbyimplementationofPAM resultedin
an impressively high concordance between known and pre-
dicted molecular subgroup afﬁliations across the three
independent cohorts (Fig. 2a–d; Supplementary Table 1;
concordance = 127/130, *98%). There was only a single
subgroup misclassiﬁcation in the Cho series (1/39), two
misclassiﬁed cases in the Kool series (2/36), and none in the
Remke series (0/55). Distribution of validation cases
appeared to faithfully represent the relative subgroup fre-
quencies that have been reported by multiple studies in the
literature (Fig. 2d) [1, 6, 12]. For sample misclassiﬁcations,
there was no apparent bias towards one particular subgroup,
although it is important to note that all Group C medullo-
blastomas in this series (n = 28) were accurately classiﬁed
usingourassay(Fig. 2d).AsGroupCmedulloblastomashave
Table 1
Gene symbol Accession Gene description Cytoband Subgroup-speciﬁc
fold-change
WNT
WIF1 NM_007191 WNT inhibitory factor 1 12q14.3 236.4
TNC NM_002160 tenascin C 9q33 65.9
GAD1 NM_000817 glutamate decarboxylase 1 (brain, 67 kDa) 2q31 63.2
DKK2 NM_014421 dickkopf homolog 2 (Xenopus laevis) 4q25 55.9
EMX2 NM_004098 empty spiracles homeobox 2 10q26.1 44.7
SHH
PDLIM3 NM_014476 PDZ and LIM domain 3 4q35 32.1
EYA1 NM_172059 eyes absent homolog 1 (Drosophila) 8q13.3 20.8
HHIP NM_022475 hedgehog interacting protein 4q28–q32 19.9
ATOH1 NM_005172 atonal homolog 1 (Drosophila) 4q22 15.6
SFRP1 NM_003012 secreted frizzled-related protein 1 8p12–p11.1 15.5
Group C
IMPG2 NM_016247 interphotoreceptor matrix proteoglycan 2 3q12.2–q12.3 15.1
GABRA5 NM_000810 gamma-aminobutyric acid (GABA) A receptor, alpha 5 15q11.2–q12 14.6
EGFL11 NM_198283 eyes shut homolog (Drosophila) 6q12 13.4
NRL NM_006177 neural retina leucine zipper 14q11.1–q11.2 11.5
MAB21L2 NM_006439 mab-21-like 2 (C. elegans) 4q31 10.9
NPR3 NM_000908 natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide receptor C)
5p14–p13 8.2
Group D
KCNA1 NM_000217 potassium voltage-gated channel, shaker-related
subfamily, member 1 (episodic ataxia with
myokymia)
12p13.32 16.4
EOMES NM_005442 eomesodermin 3p21.3–p21.2 13
KHDRBS2 NM_152688 KH domain containing, RNA binding,
signal transduction associated 2
6q11.1 10.8
RBM24 NM_153020 RNA binding motif protein 24 6p22.3 10.7
UNC5D NM_080872 unc-5 homolog D (C. elegans) 8p12 10.7
OAS1 NM_016816 20,50-oligoadenylate synthetase 1, 40/46 kDa 12q24.1 10.5
Acta Neuropathol (2012) 123:615–626 619
123aninferiorprognosis[1,12],itisencouragingthatcasesofthis
afﬁliation were classiﬁed with high accuracy. Although there
isnotruegoldstandardforsubgroupassignmentasdiscussed
above, we conclude that our nanoString assay is highly reli-
able for determination of subgroup afﬁliation.
Reproducibility and cross-site validation
of the nanoString CodeSet
An ideal clinical test should be consistent and reproducible
across different geographic locales and in different labo-
ratories. To determine whether our custom nanoString
assay could reliably produce comparable data when
performed at different technical sites, we shipped 48
samples from our training series to two additional nano-
String-equipped genomic facilities at the University of
Miami (USA) and the University of Geneva (Switzerland).
Randomization of samples and masking of their associated
subgroup status allowed us to perform class prediction
analysis on the data generated in Miami and Geneva. All
cases analyzed at these two international facilities were
assigned to the correct molecular subgroup (Fig. 3a–c;
Supplementary Table 2). Inspection of expression heatm-
aps from data generated at the independent nanoString
facilities shows that the results are virtually indistinguish-
able (Fig. 3a–c). Scatterplot analysis of the Toronto data
SHH WNT Group C Group D
WIF1
TNC
GAD1
DKK2
EMX2
PDLIM3
EYA1
HHIP
ATOH1
SFRP1
IMPG2
GABRA5
EGFL11
NRL
MAB21L2
NPR3
KCNA1
EOMES
KHDRBS2
RBM24
UNC5D
OAS1
CodeSet
Medulloblastoma classifier: exon array data (n=101)
SHH WNT Group C Group D
WIF1
TNC
GAD1
DKK2
EMX2
PDLIM3
EYA1
HHIP
ATOH1
SFRP1
IMPG2
GABRA5
EGFL11
NRL
MAB21L2
NPR3
KCNA1
EOMES
KHDRBS2
RBM24
UNC5D
OAS1
CodeSet
Medulloblastoma classifier: nanoString data (n=101)
Predicted classes for training samples (n = 101)
C
l
a
s
s
 
p
r
e
d
i
c
t
i
o
n
 
m
e
t
h
o
d
Mult
LDA
KNN.9
SVM.Radial
PAM
Actual
Unreliable WNT SHH GroupC GroupD
WNT SHH Group C Group D
OAS1
UNC5D
RBM24
KHDRBS2
EOMES
KCNA1
NPR3
MAB21L2
NRL
EGFL11
GABRA5
IMPG2
SFRP1
ATOH1
HHIP
EYA1
PDLIM3
EMX2
DKK2
GAD1
TNC
WIF1
(b)
Exon array expression
n
a
n
o
S
t
r
i
n
g
 
e
x
p
r
e
s
s
i
o
n
0
5
10
15
r = 0.86
6 8 10 12 14
p < 1e−15
-1.0 1.0 0
-1.0 1.0 0
(a)
(c)
(d)
Fig. 1 A nanoString CodeSet for medulloblastoma subgroup assign-
ment. a Expression heatmaps for 22 medulloblastoma signature genes
in a series of 101 primary medulloblastomas (training series) proﬁled
by both the nanoString nCounter System (upper panel) and by
Affymetrix exon array (lower panel). The 22 signature genes
comprise the nanoString CodeSet used throughout the study. b Pear-
son correlation analysis of nanoString expression data versus
Affymetrix expression data for the 22 signature genes shown in
a across the training series of 101 medulloblastomas. r = Pearson
correlation. c Virtual heatmap depicting results of cross-validation
analysis for multiple class prediction algorithms evaluated on the
training series for medulloblastoma subgroup prediction accuracy.
Samples are ordered horizontally according to their known subgroup
afﬁliation (‘Actual’). Results represent the consensus subgroup
assignment following 10,000 iterations and discordant cases are
labeled according to the subgroup in which they were erroneously
classiﬁed. Samples labeled in grey represent those in which a single
subgroup could not be reliably assigned. d Centroid plot for the
nanoString CodeSet as determined by the PAM algorithm. Genes are
grouped according to the subgroup for which they exhibit a positive
centroid value
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123versus the data from the two validation sites established an
extremely high degree of correlation (Toronto/Miami,
r = 0.97; Toronto/Geneva, r = 0.98). We conclude that
our nanoString approach to medulloblastoma subgroup
assignment is highly reproducible across different centers,
making it highly suitable in the context of a clinical trial.
Accurate classiﬁcation of archival formalin-ﬁxed
parafﬁn embedded (FFPE) medulloblastomas
Most conventional technologies employed for quantiﬁca-
tion of mRNA abundance (i.e., gene expression arrays,
q-RT-PCR, RNA-Seq) require high-quality RNA that
exhibits little to no degradation. Nucleic acid (including
RNA) extracted from tissue stored as FFPE material is
typically highly degraded and fragmented, and therefore
not suitable for most molecular proﬁling platforms. As
nanoString relies on relatively short pairs of 50mer probes
[5], it exhibits robust performance on RNA extracted from
FFPE material with results comparable to those obtained
with RNA from fresh-frozen tissue [15].
We applied our nanoString assay to a series of 84 FFPE
cases obtained from three independent institutions in three
different countries: Hospital for Sick Children (Toronto,
Canada), Johns Hopkins University (Baltimore, USA) and
theDKFZ(Heidelberg,Germany).Foreachofthesecohorts,
molecular subgroup afﬁliation had been previously deter-
mined using either gene expression array proﬁling of
matched frozen tissue, or IHC-based classiﬁcation. Bioana-
lyzer analysis of FFPE-derived RNA conﬁrmed all samples
had highly degraded RNA (Supplementary Table 3, median
RNA Integrity Number (RIN) value = 2.4). NanoString
proﬁling followed by PAM class prediction resulted in
accurate classiﬁcation of 57/84 (*68%) FFPE cases (Sup-
plementary Table 3), a success rate signiﬁcantly lower than
that achieved for fresh-frozen cases (*98%). In order to
(b) (a)
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Fig. 2 Validation of nanoString assay on multiple published medul-
loblastoma cohorts with known subgroup afﬁliation. a–c Expression
heatmaps of nanoString class-predicted medulloblastomas of known
subgroup status as published by Remke et al. (a), Cho et al. [1]( b),
and Kool et al. [6]( c). Samples were sorted according to subgroup
prediction as determined by nanoString. nanoString predicted
subgroup, known expression subgroup afﬁliation, and erroneously
classiﬁed cases are marked above the heatmap. d Left chart Pie chart
showing the known subgroup distribution of medulloblastomas from
the three independent cohorts analyzed in a–c (n = 130) and the
class-predicted subgroup assignments as determined by nanoString
proﬁling. Misclassiﬁed cases are marked within each pie segment
according to the subgroup in which they were erroneously classiﬁed.
Right chart Pie chart showing the class prediction success rate
(*98%, 127/130) for the validation series
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123identifycasesinwhichRNAextractedfromFFPEwasnotof
sufﬁcient quality for nanoString to conﬁdently assign sub-
group,weestablishedaminimalPAMprobabilitythreshold,
proceeding only with those FFPE samples where PAM
provided a high conﬁdence subgroup assignment. Class
predictionaccuracyofvalidationsamplesdecreaseswiththe
PAM probability score at two distinct stages (Fig. 4a). The
initial decline in accuracy can be explained by inclusion of
poor-quality samples, whereas the second decline can be
attributedtodeteriorationofclasspredictionperformanceby
PAM (Supplementary Figure 5a). The initial probability
threshold was therefore set at the point just prior to the sec-
ond decline in accuracy (PAM probability = 0.75). After
ﬁltering based on this probability threshold, the effect of
FFPE sample age on class prediction performance was
assessed in order to determine an age cut-off for FFPE
samples. After limiting our analysis to FFPE cases from the
last 8 years, PAM accurately classiﬁed C95% of cases
(Fig. 4b; Supplementary Table 3).
As the threshold for accurate subgroup assignment
varied by subgroup, probability thresholds were re-estab-
lished in a subgroup-speciﬁc manner using cases from the
last 8 years (Supplementary Figure 5b). The new proba-
bility thresholds were chosen to maintain a near 100% class
prediction accuracy in high-quality samples (WNT = 0.7,
SHH = 0.5, Group C = 0.5, Group D = 0.5). In recent
FFPE samples (B8 years, n = 32), PAM conﬁdently pre-
dicted subgroups for 28/32 cases (87.5%) (Fig. 4c, d). In
4/32 (12.5%) cases PAM was unable to provide a high
conﬁdence subgroup assignment, suggesting that our cur-
rent nanoString assay is incapable of sub-grouping them,
and that alternative methods would be necessary (Fig. 4d).
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Fig. 3 Cross-site validation of medulloblastoma classiﬁcation using
the nanoString CodeSet. a–c Forty-eight primary medulloblastomas
of known subgroup afﬁliation were analyzed using the nanoString
CodeSet at three independent facilities: Toronto, Canada (a), Miami,
USA (b), and Geneva, Switzerland (c). Class prediction analysis of
the data generated at the three independent nanoString facilities
resulted in 100% sample classiﬁcation accuracy. Heatmaps of the
normalized nanoString data for the 48 cases are shown. d Scatterplot
showing correlation of nanoString expression data generated in
Toronto versus that generated at the two international validation sites
(Miami, USA and Geneva, Switzerland). r = Pearson correlation
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123Notably, 2/4 cases that failed to meet the PAM threshold
were in fact accurately classiﬁed by our nanoString assay
(Supplementary Table 3). For those FFPE cases in which
the PAM threshold was exceeded, 28/28 (100%) were
assigned to the correct subgroup (Fig. 4c). Multiple logistic
regression analysis established that sample age was a more
reliable predictor of class prediction accuracy than mea-
sures of RNA integrity (i.e., RIN and RNA size)
(Supplementary Figure 6). These results conﬁrm the com-
patibility of our custom nanoString CodeSet with recent
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Fig. 4 Compatibility of nanoString classiﬁcation assay with forma-
lin-ﬁxed parafﬁn embedded (FFPE) material from archival samples.
a Plot of nanoString class prediction accuracy for all 280 validation
samples according to PAM probability score. Vertical red line
denotes threshold at which PAM classiﬁcation becomes unreliable.
b Plot of nanoString class prediction accuracy according to sample
age of archival medulloblastomas stored as FFPE material (n = 84).
Samples obtained within the past 8 years exhibit an accuracy of
C95%, as demarcated by the red vertical line on the plot. Sample age
range for the FFPE series was 1–33 years, with a median sample age
of 10 years. c Heatmap of nanoString data showing class prediction
results for FFPE cases B8 years of age conﬁdently predicted by PAM
(n = 28). 28/28 cases (100%) meeting the threshold were assigned to
the correct subgroup. Samples were sorted according to subgroup
prediction as determined by nanoString. d NanoString data for FFPE
cases B8 years of age that failed to meet the PAM probability
threshold for subgroup assignment (n = 4). 2/4 cases that failed to
meet the PAM threshold, and were not assigned to the correct
subgroup
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123FFPE-derived material, and strongly suggest that our
nanoString assay for medulloblastoma classiﬁcation is well
suited to the clinical trial setting in which recent FFPE
samples are readily available.
Discussion
Current criteria for risk stratiﬁcation of medulloblastoma
patients include patient age, metastatic status, and extent of
surgical resection. Patients over the age of three with non-
metastatic disease that is gross totally resected are consid-
ered average-risk, and all others deemed high-risk. This
current stratiﬁcation scheme fails to account for the exten-
sive prognostic variability that exists between molecular
subgroups. Therefore, the next generation of prospective
clinical trials for medulloblastoma will almost certainly
include molecular subgroup assignment for both patient
stratiﬁcation, and patient selection for targeted therapies. In
particular, modulation of the intensity of therapy in a sub-
group-speciﬁc manner is a very attractive approach in order
to improve outcomes for patients. For example, WNT
subgroup medulloblastomas are rarely metastatic and have
progression-free and overall survival rates of[90% [1, 2, 4,
12, 14]; in contrast, patients with Group C medulloblastoma
have a dismal prognosis [1, 12]. Molecular subgroup-based
risk stratiﬁcation will permit a more rational and person-
alized approach to patient treatment. Furthermore, targeted
therapies against activated signaling pathways such as those
that attenuate SHH pathway activation currently being
evaluated in clinical trials [8] will beneﬁt from subgroup-
based stratiﬁcation as they will likely only be effective in
one of the four subgroups.
We describe a novel molecular classiﬁcation method for
medulloblastoma that relies on the nanoString nCounter
System. This technology requires minimal RNA input
(*100 ng), does not involve any enzymatic ampliﬁcation,
and produces expression data that are highly correlative
with data generated by expression arrays. The nanoString-
mediated subgroup assay described in this report was sig-
niﬁcantly more cost effective than performing the
equivalent classiﬁcation using an array-based approach,
averaging *$60 USD per sample for our nanoString
assay compared to *$425 USD per sample for a modern
Affymetrix expression array. Using the expression pattern
of only 22 medulloblastoma subgroup-speciﬁc signature
genes we have established an assay that effectively assigns
fresh-frozen medulloblastomas to the correct subgroup
with *98% accuracy as conﬁrmed using three independent
validation cohorts. Schwalbe et al. [16] recently described
a 13-gene multiplex qPCR-based expression assay to
classify medulloblastomas into either WNT, SHH, or non-
WNT/SHH subgroups. Unsupervised analyses were used in
this study to establish the ability of the 13-gene signature to
recapitulate subgroup data previously determined in mul-
tiple published gene expression cohorts. Although this
method proved capable of placing samples into WNT,
SHH, and non-WNT/SHH categories, the technique was
not directly evaluated on samples belonging to the pub-
lished cohorts, nor did the assay attempt to make the
important distinction between Group C and Group D
medulloblastomas, conﬁrmed in multiple recent studies to
be both genetically and clinically distinct [1, 6, 12]. In the
current study, we have obtained a subset of the same fresh-
frozen RNA samples that were used in three independent
microarray-based medulloblastoma sub-grouping studies
and validated our nanoString assay directly on these tem-
plates (n = 130). Class prediction analysis conﬁrmed the
accuracy of our assay in *98% of cases establishing the
validity of our protocol. For samples that were misclassi-
ﬁed, it is difﬁcult to verify the source of the discrepancy
regarding subgroup assignment, although possible expla-
nations could be related to erroneous results of our
nanoString assay, potential sample mix-ups, or erroneous
classiﬁcation in the original gene expression array
proﬁling.
We previously introduced an IHC-based classiﬁcation
scheme for sub-grouping medulloblastoma using only four
commercially available antibodies [12]. This IHC-based
method is very robust in our laboratory; although challenges
remain in making the technique generalizable, including
variability in antibody batches, sample preparation meth-
ods, staining procedures, and inter-observer reliability. We
would suggest that in the future, IHC-based methods could
be used in concert with a nanoString-based assay to provide
clinicians with a high conﬁdence assignment of subgroup
for clinical medulloblastoma samples. The two methods are
orthogonal, and highly complimentary.
To test the reproducibility of our nanoString-based
classiﬁcation assay across different centers, we analyzed a
series of 48 cases at nanoString facilities in Toronto, Miami,
and Geneva. The expression data generated at the three
international sites were virtually indistinguishable, and
produced correlation coefﬁcients of C0.97. This impressive
level of reproducibility achieved using the nanoString
technology suggests that our assay could produce identical
results at any institute equipped with the nanoString
nCounter System, or that RNA samples from centers around
the world could be studied at a central location.
Pathologists have long stored tumor biopsies as FFPE
material in order to preserve as much cellular and structural
integrity of the original tumor specimen as possible,
making samples amenable to study for decades. A signiﬁ-
cant drawback associated with this preservation technique
is that DNA and RNA extracted from FFPE material is
typically highly degraded, and therefore of limited use in
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123molecular studies. The nanoString technology has known
compatibility with degraded RNA isolated from FFPE
cases [15], largely due to the usage of relatively short
50mer probes [5]. In a large series of 84 FFPE medullo-
blastomas from three independent pathology labs, our
nanoString assay could assign subgroup with high conﬁ-
dence in 87.5% of cases from the last 8 years. Of those
FFPE cases with a high conﬁdence subgroup assignment,
100% were accurately classiﬁed as compared to the gold
standard of expression proﬁling. Although 2/4 FFPE cases
that failed to meet the PAM threshold were assigned to the
correct subgroup, we suggest that higher speciﬁcity at the
expense of sensitivity is necessary for a biomarker in the
setting of a clinical trial.
In conclusion, we have developed, optimized, and val-
idated a novel assay for medulloblastoma sub-grouping
that is compatible with conditions common to current
clinical trial settings. Future incorporation of this or similar
molecular classiﬁcation pipelines into prospective clinical
trials will enhance our current understanding of the bio-
logical and prognostic signiﬁcance of medulloblastoma
subgroups, and we anticipate that this information will lead
to improved care and outcomes for our patients.
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